MMW - Fortschritte der Medizin

, Volume 158, Supplement 2, pp 43–46 | Cite as

Beziehung als Risiko

HIV-negative Partner sollen das auch bleiben!

  • Heiko Jessen

Paare werden als „serodiskordant“ bezeichnet, wenn nur einer von ihnen mit HIV infiziert ist. Normalerweise bleibt es nicht dabei, und dies ist einer der wichtigsten Faktoren der globalen HIV-Epidemie. Dabei lässt sich die Infektion über den Partner heutzutage gut verhindern.

HIV & relationship — what if only one of the partners is HIV positive?


HIV serodiscordant couple pre-exposure prophylaxis treatment as prevention 


  1. 1.
    Jiwatram-Negron T, El-Bassel N. Systematic Review of Couple-Based HIV Intervention and Prevention Studies: Advantages, Gaps, and Future Directions. AIDS Behav. 2014;18:1864–87CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chemaitelly H, Cremin I, Shelton J et al. Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect. 2012;88:51–7CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chemaitelly H, Shelton JD, Hallett TB, Abu-Raddad LJ. Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. Aids. 2013;27:251–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Goodreau SM, Carnegie NB, Vittinghoff E et al. What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One. 2012;7:e50522CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: September 2015.
  6. 6.
    Nelson LJ, Beusenberg M, Habiyambere V et al. Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines. Aids. 2014;28(Suppl 2):S217–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Levi J, Raymond A, Pozniak A et al. Can the UNAIDS 90-90-90 target be achieved? Analysis of 12 national level HIV treatment cascades. 8th IAS Conference on HIV Pathogenesis Treatment and Prevention Vancouver, Canada 18-22 July 2015. Scholar
  8. 8.
    Savasi V, Mandia L, Laoreti A, Cetin I. Reproductive assistance in HIV serodiscordant couples. Hum Reprod Update. 2013;19:136–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Sullivan PS, Wall KM, O’Hara B et al. The prevalence of undiagnosed HIV serodiscordance among male couples presenting for HIV testing. Arch Sex Behav. 2014;43:173–80.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bobashev G, Norton J, Wechsberg W, Toussova O. Are you HIV invincible? A probabilistic study of discordant couples in the context of HIV transmission. PLoS One. 2014;9:e94799.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kahle EM, Hughes JP, Lingappa JR et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62:339–47.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Purcell DW, Mizuno Y, Smith DK et al. Incorporating couples-based approaches into HIV prevention for gay and bisexual men: opportunities and challenges. Arch Sex Behav. 2014;43:35–46.CrossRefPubMedGoogle Scholar
  13. 13.
    World Health Organization. Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people: recommendations for a public health approach. Geneva, Switzerland: 2011. S. 36.
  14. 14.
    Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Baggaley RF, White RG, Hollingsworth TD, Boily MC. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology. 2013;24:110–21.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Persson A. ‚The world has changed‘: Pharmaceutical citizenship and the reimagining of serodiscordant sexuality among couples with mixed HIV status in Australia. Sociol Health Illn. 2016;38:380–95CrossRefPubMedGoogle Scholar
  17. 17.
    McGowan I. An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol. 2014;71:624–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Molina JM et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. CROI 2015. 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015), 23-26 February 2015, Seattle, Washington, USA. Oral late breaker abstract 23LB.Google Scholar
  19. 19.
    McCormack S et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gulick R. HPTN 069/ACTG 5305: Phase II Study of Maraviroc-Based Regimens for HIV PrEP in MSM. CROI 2016, Abstract 103Google Scholar
  21. 21.
    Markowitz M. ÉCLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men. CROI 2016, Abstract 106Google Scholar
  22. 22.
    Whetham J, Taylor S, Charlwood L et al. Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. AIDS Care. 2014;26:332–6CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin 2016

Authors and Affiliations

  1. 1.Praxis Jessen2 + KollegenBerlinDeutschland

Personalised recommendations